Celcuity Shares Surge After Gedatolisib Shows 76% Reduction in Disease Progression
Celcuity shares jump 45% after Phase 3 trial shows gedatolisib significantly improves survival in HR+/HER2- breast cancer patients. Analysts raise price target to $95.